Professional Summary
Professional Overview
Gabriel Cohn is an experienced Chief Medical Officer with a strong background in the biotechnology and pharmaceutical industries. He specializes in clinical development, medical affairs, and translational medicine, with a particular focus on rare genetic diseases and women's health.
Current Role
As the Chief Medical Officer at iECURE, Inc., Gabriel is responsible for overseeing the company's clinical development programs and medical strategy. He plays a crucial role in advancing the company's gene therapy pipeline and ensuring the highest standards of patient safety and efficacy. Additionally, Gabriel serves as the Executive Director of the Rosenau Family Research Foundation, where he leads initiatives to support innovative research and development in the life sciences.
Career Progression
Prior to his current roles, Gabriel held various leadership positions at prominent biotechnology companies, including Homology Medicines, Inc., AVROBIO, and OvaScience. He has extensive experience in clinical trial design, regulatory affairs, and cross-functional collaboration. At Shire Pharmaceuticals, Gabriel made significant contributions to the development and commercialization of treatments for Gaucher disease and other rare genetic disorders.
Academic Background
Gabriel Cohn holds a Doctor of Medicine (M.D.) degree and is board-certified in Medical Genetics and Obstetrics and Gynecology. He completed his medical training at SUNY Health Science Center in Syracuse and Baystate Medical Center, where he also served as the Medical Director of Genetic Services and the Chief of Clinical and Reproductive Genetics.
Areas of Expertise
- Clinical development and trial design
- Medical affairs and translational medicine
- Rare genetic diseases and women's health
- Gene therapy and gene editing technologies
- Cross-functional leadership and collaboration
Professional Impact
Throughout his career, Gabriel has played a pivotal role in advancing the understanding and treatment of rare genetic diseases. He has been involved in the development and commercialization of several important therapies, and his work has had a significant impact on improving patient outcomes. Gabriel's expertise, strategic vision, and collaborative approach have earned him a respected reputation within the biotechnology and pharmaceutical industries.
Conclusion
With his extensive experience, proven track record of success, and commitment to innovation, Gabriel Cohn is well-positioned to continue making meaningful contributions to the life sciences field as a highly accomplished Chief Medical Officer and industry leader.
